Cancer Microenvironment
Cancer Microenvironment
The Cancer Microenvironment (CM) research program leverages expertise in immunology, stem cell biology, radiobiology, and nanotechnology, to investigate how the tumor microenvironment impacts the way cancer arises, progresses, and responds to therapy. Collaboration is essential, and program members are particularly focused on translational research that impacts myeloid and lymphoid malignancies and pancreatic cancer.
The specific aims of the CM program are:
- To disrupt and reprogram cancer-promoting microenvironments.
- To restore normal tissue homeostasis from cancer and cancer treatment-induced injury.
The goals of this high-impact basic science program complement the work done at Wilmot’s Genetics, Epigenetics, and Metabolism (GEM) research program, and its Cancer Prevention and Control (CPC) program, and involves collaboration with the Community Outreach and Engagement (COE) office to meet the needs of Wilmot’s 27-county catchment area.
Program Leaders
Scott Gerber, Ph.D.
Associate Professor, Surgery/Research
Dr. Gerber is a tumor immunologist whose laboratory focuses on harnessing the immune system to recognize and kill cancerous cells.
Laura Calvi, M.D.,
Professor of Medicine, Neurosurgery, and Pharmacology and Physiology
Dr. Calvi is focused on bridging bone and stem cell biology to discover the regulatory components of the bone marrow microenvironment, to identify targeted therapies.
To view a full list of members and search by program, visit our research members page.